HanchorBio Inc.
HanchorBio Inc.
Explore linked clinical trials.2 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1 Study of HCB303 in Participants With Advanced Malignancies | Advanced Malignancies | Not yet recruiting | Phase 1 | 2026-10-05 | NCT07859228 | |
| An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors | Bone Diseases, Developmental, Camurati-Engelmann disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, bone disorder, hereditary disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, musculoskeletal system disorder, neoplasm, osteochondrodysplasia | Recruiting | Phase 1 | 2026-04-13 | NCT06487624 |